Clinical benefits of novel non-nucleoside reverse transcriptase inhibitors: A prospective cohort study.
Immun Inflamm Dis
; 12(4): e1217, 2024 Apr.
Article
em En
| MEDLINE
| ID: mdl-38578026
ABSTRACT
INTRODUCTION:
The efficacy and safety of ainuovirine+lamivudine+tenofovir (ANV+3TC+TDF) and efavirenz+lamivudine+tenofovir (EFV+3TC+TDF) have been confirmed in previous clinical trials; however, there are no related studies on patient-reported outcomes. This study aimed to evaluate the effectiveness and safety of these 2 antiretroviral therapy regimens and to understand the patient's symptom experience and subjective experience of sleep quality through patient-reported outcomes.METHODS:
This is a single-center prospective cohort study with 243 patients evaluated from October 1, 2021 to June 30, 2022. Virological effectiveness and patient-reported outcomes results were analyzed. The primary endpoint was the proportion of HIV viral load <50 copies/mL (virological suppression rate) at 48 weeks and the changes in the HIV symptom index and Pittsburgh sleep quality index.RESULTS:
The virological suppression rates in the ANV+3TC+TDF and EFV+3TC+TDF groups were 83.6% (102/122) and 87.6% (106/121), respectively, at 48 weeks. In the ANV+3TC+TDF group, the scores of HIV symptom index and pittsburgh sleep quality index in the 48th week were lower than the baseline level (p < 0.05). Logistic regression results showed that the baseline regimen EFV+3TC+TDF was a risk factor for dizziness/lightheadedness (odds ratio = 3.153, 95% confidence interval 1.473-6.748, p = 0.003), sadness/depression odds ratio = 2.404, 95% confidence interval1.188-4.871, p = 0.015), and difficulty sleeping (odds ratio = 2.802, 95% confidence interval 1.437-5.463, p = 0.002) at 48 weeks.CONCLUSIONS:
Both regimens showed good virological effectiveness; however, compared with ANV+3TC+TDF, the EFV+3TC+TDF regimen reduced the prevalence of HIV-related symptoms.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Contexto em Saúde:
2_ODS3
Problema de saúde:
2_enfermedades_transmissibles
Assunto principal:
Infecções por HIV
/
Fármacos Anti-HIV
Limite:
Humans
Idioma:
En
Revista:
Immun Inflamm Dis
/
Immun. Inflamm. Dis
/
Immunity, inflammation and disease
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
China